Mycophenolate Versus Azathioprine for Kidney Transplantation: A 15-Year Follow-Up of a Randomized Trial.
Clayton PA, McDonald SP, et al.Transplantation, 94(2):152-158, 2012.
Aims
To compare the long-term outcomes of immunosuppressive therapy with mycophenolate versus azathioprine in kidney transplant recipients.
Interventions
Azathioprine (100 mg daily if body weight <75 kg; 150 mg daily if body weight >75kg) versus 2 g/d mycophenolate mofetil (MMF) or 3 g/d MMF. All patients received cyclosporine and corticosteroids.
Participants
133 Australian patients who received a deceased donor kidney transplant.
Outcomes
The primary outcomes were patient and graft survival, graft failure defined as death or permanent loss of graft function. Secondary outcomes were death-censored graft survival, cancer incidence, kidney function measured as serum creatinine concentration and estimated glomerular filtration rate.
Follow-up
15 years
CET Conclusions
There was a 15 years follow up of the cohort of Australian and New Zealand patients entered in the Tricontinental Mycophenolate Mofetil Renal Transplantation Study. In the 133 patients entered into the three arms of the trial (azathioprine and 2G and 3G MMF) no difference was found in any of the outcomes examined. Thus there was no evidence that MMF was superior to Azathiaprine.
Data analysis
Available case analysis
Trial registration
Not reported